Genedrive PLC - Interim Results to 31 December 2025
genedrive plc
("genedrive" or the "Company")
Interim results to
- Capitalised to expand commercial operations in the
- Focused on commercial delivery across markets in the near-term
genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces unaudited interim results for the six months to
Operational Highlights (including post period end)
Genedrive® CYP2C19
- Genedrive® CYP2C19 ID Kit in use at Salford Hyper Acute Stroke Unit, the largest in
England , initially as part of a national pilot programme to support broader healthcare system adoption - NHS implementation guidance published for CYP2C19 testing in stroke pathways, supporting local adoption and including the Genedrive® CYP2C19 ID Kit as a rapid testing option
- Accepted onto the NHS Dynamic Procurement System (DPS) to support NHS adoption
- 12-Month expansion of use study underway to include Acute Coronary Syndrome (ACS), led by the Manchester University NHS Foundation Trust
Scotland's NHS Grampian and Western Isles assessing Genedrive® CYP2C19 ID Kit as a "test of change" to support adoption for remote and rural patients acrossScotland - International market access routes and reimbursement strategies assessed in
Europe and theMiddle East - US 510(k) pathway defined for US market entry, following completion of required studies
Genedrive® MT-RNR1
- Genedrive® MT-RNR1 ID Kit currently in use across 14 hospitals in the
UK as part of the ongoing PALOH-UK programme for NICE Evidence Generation - More than 30 critically ill babies identified with MT-RNR1 variant, enabling alternative antibiotic prescription and reducing risk of aminoglycoside-induced lifelong hearing loss (AIHL)
- Accepted onto the NHS Dynamic Procurement System (DPS) to support NHS adoption
Scotland national phased roll-out underway with first implementation at the Royal Hospital for Children inGlasgow with Royal Alexandra Hospital and Princess Royal Maternity Hospital expected to roll out in 2026- Implemented at
Dublin's Rotunda Hospital to support wider routine clinical use nationally Kingdom of Saudi Arabia's Ministry of Health signed a Memorandum of Understanding for Medical Equipment Technology to implement a national pilot study using the Genedrive® MT-RNR1 ID kit under the "Generations Hear" national initiative
Financial Highlights (including post period)
- Equity fundraise raising circa
£4.9m after expenses completed inMarch 2026 of which£0.6m received inFebruary 2026 which funded near-term working capital requirements £0.5m shareholder loan converted into equity concurrently with the equity fundraise- Cash of
£3.65m as at27 March 2026 and debt free - Revenue and other income of
£0.57m (H1 2024/5:£0.35m ) - Diagnostics costs of
£2.3m (H1 2024/5:£2.1m ) - Operating loss of
£2.6m (H1 2024/5:£2.6m ) - Cash of
£0.4m as at31 December 2025 (30 June 2025 :£1.2m )
"The strengthened financial position following the recent fundraise provides the resources and stability to support operational expansion, product development, and market access initiatives. We will continue to engage with NHS stakeholders, ICBs, senior NHS and government stakeholders and international partners to drive adoption and implementation of our technologies, while closely monitoring market and funding dynamics to ensure resilience and adaptability in an evolving healthcare environment.
"Whilst market conditions and local NHS funding constraints have been challenging, the Board anticipates an improvement in the new NHS financial year (commencing in April) in a phased process that could take up to 12 months. The Board is confident in the strategy and remains committed to delivering innovative diagnostic solutions, expanding market reach, and generating sustainable value for shareholders."
|
genedrive plc |
+44 (0)161 989 0245 |
|
Gino Miele: CEO / Russ Shaw: CFO |
https://investors.genedrive.com/s/e0025c
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
5654 & Company (Media & Investor Relations) |
|
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
CHIEF EXECUTIVE OFFICER'S AND CHAIRMAN'S REPORT
Introduction
During the period, the Company has remained focused on advancing its pharmacogenetic testing solutions, while navigating an ever-evolving healthcare landscape. The UK National Health Service (NHS) continues to undergo structural and strategic transformation, with Integrated Care Boards (ICBs) assuming an increasingly central role in commissioning and funding decisions. At the same time, broader geopolitical and economic factors have influenced both market access and capital availability. Despite these dynamics, we have made meaningful progress in positioning ourselves for near and long-term commercial growth.
Post-period funding and scale up
A key recent achievement has been successfully securing
The Company's post-period capital raise is focused on supporting continued near-term commercialisation and market expansion activities across the UK, Europe and the Middle East for both pharmacogenetic tests. Key priorities include progressing in-country registrations in target geographies and supporting pilot phase implementations to drive early adoption and real-world evidence generation.
Proceeds from the fundraise will also support operational, strategic and product development expenditure, including:
- FDA 510(k) submission for Genedrive® CYP2C19 currently anticipated around
June 2026 , pending completion of studies, with an expected 3-4 month review period post submission - Manufacturing scale-up and delivery of operational efficiencies
- User-led, on-market refinements to enhance product usability and workflow integration
- Translation and expansion of the Company's IP to include a laboratory-based CYP2C19 genotyping assay alongside the point-of-care offering
The Board believes these initiatives position the Company to transition from early commercial activity into a more scalable revenue phase, supported by the strengthened financial position post the recent fundraise.
Product performance
Genedrive® CYP2C19
Product and operational performance
The Genedrive® CYP2C19 ID Kit is currently in use at Salford Hyper Acute Stroke Unit, the largest in England, initially as part of a national pilot programme to support broader commercial adoption across healthcare systems.
In December, Genedrive's CYP2C19 ID Kit was implemented into Scottish NHS Grampian (Dr. Gray's Hospital, Elgin) and NHS Western Isles (Western Isles Hospital, Stornoway) under a "test of change" pilot programme for stroke patients in remote and rural settings. Whilst the pathway for CYP2C19 genotyping in NHS Scotland currently relies on laboratory testing, the Centre For Sustainable Delivery, commissioned by the Scottish Government, is assessing the impact of rapid genetic testing using the Genedrive CYP2C19 ID kit, which will run for approximately one year and include c.400 patients. The evidence gathered from this programme will support the business case for wider deployment across Scotland.
Regulatory and market access
In December, the NHS implementation guide for CYP2C19 genotype testing to guide Clopidogrel use after ischaemic attack (IS) or transient ischaemic attack (TIA) was published, confirming the value of rapid testing solutions to stroke patients.
This guidance builds on the earlier National Institute for Health and Care Excellence (NICE) recommendation for CYP2C19 testing, which includes the Genedrive® CYP2C19 ID Kit as the preferred rapid testing option, as well as interim results from a national pilot programme comparing both laboratory and "rapid testing" approaches.
The interim results, presented at the UK Stroke Forum in November by authors from NHS England (NHSE) Network of Excellence in Pharmacogenomics, the NHSE Genomics Unit, NHSE National Stroke Programme, and Manchester Centre for Genomic Medicine, demonstrated that implementation of Genedrive® CYP2C19 testing was feasible, scalable and effective in providing immediate availability of results during acute clinical settings.
Genedrive® CYP2C19 ID Kit has been accepted onto the NHS Dynamic Procurement System (DPS); an innovative procurement process that has been developed to streamline and accelerate access to cutting-edge medical technologies permitting direct procurement by regional NHS trusts.
genedrive continues to evaluate CYP2C19 testing in other indications. As announced in May, a 12-month expansion of use study is currently underway to include Acute Coronary Syndrome (ACS), led by the Manchester University NHS Foundation Trust in collaboration with the Genotype Guided Primary Coronary Intervention ("GUIDE PCI") programme and the British Heart Foundation ("BHF") Centre of Excellence. The study is assessing the value and feasibility of rapid point of care CYP2C19 testing in cardiovascular disease to improve patient outcomes.
Beyond the UK, genedrive has continued to progress market expansion across Europe, the US and the Middle East. Key priorities include progressing in-country registrations in target regions and supporting pilot phase implementations to drive early adoption and real-world evidence generation. In the US, the Company defined the 510(k) pathway via FDA Breakthrough Device.
Genedrive® MT-RNR1
Product and operational performance
The Genedrive® MT-RNR1 ID Kit currently in use across 14 hospitals in the UK as part of the ongoing PALOH-UK programme and, to date, more than 30 critically ill babies have been identified with MT-RNR1 variant, enabling alternative antibiotic prescription and reducing the risk of aminoglycoside-induced lifelong hearing loss (AIHL).
In
In
Regulatory and market access
The PALOH-UK programme has continued to progress strongly during the period, demonstrating the strong clinical utility and feasibility of rapid MT-RNR1 Testing in neonatal care. This reinforces the potential for genedrive's technology to become a valuable tool within modern diagnostic pathways. The Company has continued to invest in product improvement to further strengthen our positioning ahead of broader market rollout.
NICE has indicated
Genedrive® MT-RNR1 ID Kit has been accepted onto the NHS Dynamic Procurement System (DPS); an innovative procurement process that has been developed to streamline and accelerate access to cutting-edge medical technologies permitting direct procurement by regional NHS trusts.
Beyond the UK, genedrive has continued to progress market expansion across key geographies. In October, the Kingdom of Saudi Arabia's Ministry of Health signed a Memorandum of Understanding with our distribution partner, iDEAL iDEA for Medical Equipment Technology to implement a national pilot study using the Genedrive® MT-RNR1 kit under the "Generations Hear" national initiative. In the US, FDA submission under the de novo Breakthrough Designation route is being planned.
The NHS 10-Year plan
The NHS 10-Year Plan places prevention firmly at the core of future healthcare delivery. This strategic direction aligns closely with the Company's value proposition, particularly in enabling early detection and proactive patient management to prevent avoidable healthcare complications. With a focus on spending decisions at ICB level, the Company is pursuing engagement with ICB stakeholders to navigate these dynamics, drive local implementation, and ensure alignment with regional priorities, positioning genedrive to benefit from future adoption pathways.
Middle East
The Middle East remains a key target market and the ongoing conflict in the region has introduced short-term uncertainty and operational challenges. The Company is closely monitoring developments while maintaining engagement with partners and stakeholders where appropriate. Despite near-term disruption, we continue to view the region as strategically important over the medium to long term.
People
The Board would like to recognise and thank our highly skilled and dedicated team, whose commitment and resilience have been instrumental in progressing the Company's strategy during a challenging period.
The Company's commercial team reduced from 11 to 4 people, primarily driven by funding constraints, which impacted staff retention and limited recruitment activity. While this has created short-term capacity challenges, the Company has remained focused on prioritising core activities and maintaining operational effectiveness.
The Board intends to rebuild capability in line with the Company's financial position and strategic priorities following the successful post-period fundraise.
Following the recent fundraise, Tom Lindsay has retired as Non-Executive Director, and we would like to express our sincere thanks for his valuable contribution and service to the Company.
Outlook
Looking ahead, the Company is well funded to build on the progress achieved during the period. The Board remains focused on executing the commercialisation of Genedrive® CYP2C19 and MT-RNR1 across the UK, Europe, and Middle East, advancing regulatory milestones including the FDA pathways, and continuing to generate real-world evidence to support broader commercial adoption in the UK.
The strengthened financial position following the recent fundraise provides the resources and stability to support operational expansion, product development, and market access initiatives. We will continue to engage with NHS stakeholders, ICBs, and international partners to drive adoption and implementation of our technologies, while closely monitoring market and funding dynamics to ensure resilience and adaptability in an evolving healthcare environment.
The Company has secured FY26 visible revenue of approximately
Current FY26 revenue visibility is underpinned by:
- NICE Early Value Assessment (EVA) evidence generation completion and submission, acting as a key catalyst for broader UK implementation
- Scotland CYP2C19 proof-of-concept pilot study, alongside phased national implementation of Genedrive® MT-RNR1 ID Kit (commenced
October 2025 ) - Manchester Foundation Trust Acute Coronary Syndrome programme and CYP2C19 rapid genotyping initiative
Whilst current market conditions and local funding constraints have been challenging, the Board anticipates an improvement from the new NHS financial year (April) in a phased process that could take up to 12 months. The Board is confident in the strategy and remains committed to delivering innovative diagnostic solutions, expanding market reach, and generating sustainable value for shareholders.
On behalf of ourselves and the Board, we would like to thank our employees, partners, collaborators, and shareholders for their continued support. We look forward to building on our growing commercial traction and delivering meaningful impact for patients through our innovative diagnostic solutions.
Dr Gino Miele
Chief Executive Officer
Dr Ian Gilham
Chairman
FINANCIAL REVIEW
Revenue and other income in the period was
Diagnostics costs were
After financing costs, the loss before taxation was
Cash Resources
The operating loss before changes in working capital and provisions for the period was
Cash flows from financing activities consisted of loan proceeds of
Closing cash was
Balance Sheet
Balance sheet net liabilities at
PRINCIPAL RISKS AND UNCERTAINTIES
There are a number of potential risks and uncertainties which could have a material impact on the Company's performance over the remaining six months of the financial year and could cause actual results to differ materially from expected and historical results. The Directors do not consider that these principal risks and uncertainties have changed materially since publication of the annual report for the year ended
UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the six months ended 31 December 2025
|
|
|
Six months ended |
Six months ended |
Year ended |
|
|
|
|
|
|
|
|
|
Unaudited |
Unaudited |
Audited |
|
|
Note |
|
|
|
|
|
|
|
|
|
|
Revenue and other income |
(3) |
570 |
350 |
954 |
|
Diagnostics costs |
|
(2,333) |
(2,058) |
(4,233) |
|
Administrative costs |
|
(856) |
(862) |
(2,101) |
|
|
|
|
|
|
|
Operating loss |
(4) |
(2,619) |
(2,570) |
(5,380) |
|
|
|
|
|
|
|
Finance costs |
(5) |
- |
- |
(89) |
|
Finance income |
(5) |
3 |
41 |
43 |
|
|
|
|
|
|
|
Loss on ordinary activities before taxation |
|
(2,616) |
(2,529) |
(5,426) |
|
Taxation |
|
175 |
200 |
195 |
|
Loss for the financial period |
|
(2,441) |
(2,329) |
(5,231) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
|
(2,441) |
(2,329) |
(5,231) |
|
|
|
|
|
|
|
Loss per share (pence) |
(7) |
|
|
|
|
- Basic |
|
(0.3)p |
(0.4)p |
(0.9)p |
|
- Diluted |
|
(0.3)p |
(0.4)p |
(0.9)p |
|
|
|
|
|
|
UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the six months ended 31 December 2025
|
|
Share Capital (unaudited) |
Other Reserves (unaudited) |
Accumulated Losses (unaudited) |
Total (unaudited) |
|
|
|
|
|
|
|
At |
8,147 |
54,656 |
(57,444) |
5,359 |
|
Equity-settled share-based payments |
- |
40 |
- |
40 |
|
Total comprehensive loss for the period |
- |
- |
(2,329) |
(2,329) |
|
At |
8,147 |
54,696 |
(59,773) |
3,070 |
|
Share issue: |
1,226 |
- |
- |
1,226 |
|
Equity-settled share-based payments |
- |
84 |
- |
84 |
|
Total comprehensive loss for the period |
- |
- |
(2,902) |
(2,902) |
|
At |
9,373 |
54,740 |
(62,675) |
1,438 |
|
Share issue: |
60 |
480 |
- |
540 |
|
Share issue: |
1 |
9 |
- |
10 |
|
Equity-settled share-based payments |
- |
38 |
- |
38 |
|
Total comprehensive loss for the period |
- |
- |
(2,441) |
(2,441) |
|
At |
9,434 |
55,267 |
(65,116) |
(415) |
UNAUDITED CONSOLIDATED BALANCE SHEET
As at
|
|
31 December |
31 December |
30 June |
|
|
2025 |
2024 |
2025 |
|
|
(unaudited) |
(unaudited) |
(audited) |
|
Note |
|
|
|
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
109 |
145 |
130 |
|
|
109 |
145 |
130 |
|
Current assets |
|
|
|
|
Inventories |
341 |
366 |
428 |
|
Trade and other receivables |
346 |
522 |
679 |
|
Current tax asset (6) |
571 |
875 |
396 |
|
Cash and cash equivalents |
387 |
2,098 |
1,182 |
|
|
1,645 |
3,861 |
2,685 |
|
|
|
|
|
|
Total assets |
1,754 |
4,006 |
2,815 |
|
|
|
|
|
|
Liabilities |
|
|
|
|
Current liabilities |
|
|
|
|
Trade and other payables |
(1,669) |
(936) |
(1,377) |
|
|
(1,669) |
(936) |
(1,377) |
|
Non-current liabilities |
|
|
|
|
Loans and borrowings |
(500) |
- |
-
|
|
|
|
|
|
|
Total liabilities |
(2,169) |
(936) |
(1,377) |
|
|
|
|
|
|
Net (liabilities) / assets |
(415) |
3,070 |
1,438 |
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
Called-up equity share capital (8) |
9,434 |
8,147 |
9,373 |
|
Other reserves (9) |
55,267 |
54,696 |
54,740 |
|
Accumulated losses |
(65,116) |
(59,773) |
(62,675) |
|
Total shareholder equity |
(415) |
3,070 |
1,438 |
|
|
|
|
|
UNAUDITED CONSOLIDATED CASH FLOW STATEMENT
For the six months ended 31 December 2025
|
|
(unaudited) |
(unaudited) |
30 June 2025 (audited) |
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities |
|
|
|
|
Loss on ordinary activities before taxation |
(2,616) |
(2,529) |
(5,426) |
|
Depreciation and amortisation on non-leased assets |
22 |
26 |
50 |
|
Depreciation on right-of-use assets |
- |
17 |
17 |
|
Finance costs |
- |
- |
89 |
|
Finance income |
(3) |
(41) |
(43) |
|
Share - based payment |
38 |
40 |
84 |
|
Operating loss before changes in working capital and provisions |
(2,559) |
(2,487) |
(5,229) |
|
Decrease / (increase) in inventories |
87 |
15 |
(47) |
|
Decrease / (increase) in trade and other receivables |
333 |
(140) |
(297) |
|
Increase / (decrease) in trade and other payables |
292 |
(486) |
(45) |
|
Net cash outflow from operations |
(1,847) |
(3,098) |
(5,618) |
|
Tax received |
- |
- |
474 |
|
Net cash outflow from operating activities |
(1,847) |
(3,098) |
(5,144) |
|
Cash flows from investing activities |
|
|
|
|
Finance income |
3 |
41 |
43 |
|
Acquisition of plant and equipment |
(1) |
(14) |
(23) |
|
Net cash inflow from investing activities |
2 |
27 |
20 |
|
Cash flows from financing activities |
|
|
|
|
Proceeds from loans and borrowings |
500 |
- |
- |
|
Proceeds from share issue |
810 |
- |
1,226 |
|
Transaction costs relating to share issue |
(260) |
- |
(89) |
|
Repayment of lease liabilities |
- |
(19) |
(19) |
|
Net inflow / (outflow) from financing activities |
1,050 |
(19) |
1,118 |
|
Net decrease in cash equivalents |
(795) |
(3,090) |
(4,006) |
|
Cash and cash equivalents at beginning of period |
1,182 |
5,188 |
5,188 |
|
Cash and cash equivalents at end of period |
387 |
2,098 |
1,182 |
|
Analysis of net funds |
|
|
|
|
Cash at bank and in hand |
387 |
2,098 |
1,182 |
NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS
1. General information
genedrive plc ('the Company') and its subsidiaries (together 'the Group') is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need pharmacogenetic platform for the diagnosis of genetic variations. The Company is a public limited company incorporated and domiciled in the UK. The address of its registered office is
The financial information for the period ended
These interim financial statements were approved by the Board of Directors on
The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods represented in these consolidated financial statements.
2. Significant accounting policies
Basis of accounting
The consolidated interim financial statements consolidate those of the Company and its subsidiaries (together referred to as the "Group"). They are presented in pounds sterling, and all values are rounded to the nearest one thousand pounds (£k) except where otherwise indicated.
Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Transactions between Group companies are eliminated on consolidation.
The accounting policies used in the preparation of the financial information for the six months ended
Going concern
The Board has reviewed the Group's financial position, cash flow forecasts, and expected revenues. Since the period end, the Company successfully completed an equity fundraise with net proceeds of
Forecasts have been prepared reflecting planned operational expenditure, regulatory and commercial activities, and ongoing investment in product development.
The Directors have concluded that it is necessary to draw attention to the revenue and cost forecasts in the business plans for the period to
The combination of the above factors represents a material uncertainty that may cast significant doubt on the Group and Company's ability to continue as a going concern.
Accordingly, the Directors have concluded that it is appropriate to continue to adopt the going concern basis of accounting in preparing these financial statements. These financial statements do not include the adjustments that would result if the Group and Company were unable to continue as a going concern.
New accounting standards adopted in the period
There have been no new accounting standards adopted in the period that have had a material impact on the financial statements.
Estimates
The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.
In preparing these interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation were the same as those that applied to the consolidated financial statements for the year ended
- determining the provision for taxation; and
- determining the carrying value for inventory
Revenue recognition
a. Product sales
Sales of goods are recognised when all the performance obligations have been completed and when the Group entity has no continuing managerial involvement nor effective control over the goods. The transfer of control of goods can pass at various points depending on the shipping terms of the contract with the customer, they can be at collection from a premises or delivery to the relevant port or customer designated premises. Where items are sold with a right of return, accumulated experience is used to estimate and provide for such returns at the time of sale.
b. Collaboration and licensing revenue
Contractually agreed upfront payments and similar non-refundable payments in respect of collaboration or licence agreements which are not directly related to ongoing research activity are recorded as deferred income and recognised as revenue over the anticipated duration of the agreement. Where the anticipated duration of the agreement is modified, the period over which revenue is recognised is also modified.
Non-refundable milestone and other payments that are linked to the achievement of significant and substantive technological or regulatory hurdles in the research and development process are recognised as revenue upon the achievement of the specified milestones.
Income which is related to ongoing research activity is recognised as the research activity is undertaken, in accordance with the contract. Activity is measured based on progress and milestones and not cost.
c. Other income - development grant funding
Income receivable in the form of Government grants to fund product development is recognised as development grant funding over the periods in which the Group recognises, as expenses, the related eligible costs which the grants are intended to compensate and when there is reasonable assurance that the Group will comply with the conditions attaching to them and that the income will be received. Government grants whose primary condition is that the Group should purchase or otherwise acquire non-current assets are recognised as deferred revenue in the Consolidated Balance Sheet and transferred to the Consolidated Statement of Comprehensive Income on a systematic and rational basis over the useful lives of the related assets.
Research and development
Research expenditure is written off as it is incurred. Development expenditure is written off as it is incurred up to the point of technical and commercial validation. Thereafter, costs that are measurable and attributable to the project are carried forward as intangible assets, subject to having met the following criteria:
- demonstration that the product will generate profitable future economic benefit and of an intention and ability to sell the product;
- assessment of technical feasibility;
- confirmation of the availability of technical, financial and other resources to complete the development;
- management intends to complete the development so the product will be available for use; and
- the expenditure attributable to the development can be reliably measured
Right-of-use assets (ROU)
At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases are recognised as an ROU asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. At the lease commencement date, a ROU asset is measured at cost comprising the following: the amount of the initial measurement of the lease liability; any lease payments made at or before the commencement date less any lease incentives received; any initial direct costs; and restoration costs to return the asset to its original condition. The ROU asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If ownership of the ROU asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.
Foreign currencies
(a) Functional and presentation currency
Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The consolidated financial statements are presented in sterling which is the Group's presentation currency.
(b) Transactions and balances
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement, except when deferred in equity as qualifying net investment hedges. Non-monetary items carried at fair value and denominated in foreign currencies are retranslated at the rates prevailing on the date when fair value is determined.
3. Revenue and other income
Revenue is measured at the fair value of the consideration received or receivable and net of discounts and sales-related taxes.
|
|
31 December |
31 December |
30 June |
|
|
2025 |
2024 |
2025 |
|
|
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
Revenue from customer contracts |
463 |
298 |
764 |
|
Grant and other income |
107 |
52 |
190 |
|
|
570 |
350 |
954 |
4. Operating segments
|
|
|
|
Diagnostic Segment |
Administrative Costs |
Total |
|
Six months ended |
|
|
£'000 |
£'000 |
£'000 |
|
Revenue and other income |
|
|
570 |
- |
570 |
|
Costs |
|
|
(2,333) |
(856) |
(3,189) |
|
Operating loss |
|
|
(1,763) |
(856) |
(2,619) |
|
Finance income |
|
|
|
|
3 |
|
Loss on ordinary activities before taxation |
|
|
|
|
(2,616) |
|
Taxation |
|
|
|
|
175 |
|
Loss for the financial period |
|
|
|
|
(2,441) |
|
|
|
|
|
|
|
|
|
|
|
Diagnostic Segment |
Administrative Costs |
Total |
|
Six months ended |
|
|
£'000 |
£'000 |
£'000 |
|
Revenue and other income |
|
|
350 |
- |
350 |
|
Costs |
|
|
(2,058) |
(862) |
(2,920) |
|
Operating loss |
|
|
(1,708) |
(862) |
(2,570) |
|
Finance income |
|
|
|
|
41 |
|
Loss on ordinary activities before taxation |
|
|
|
|
(2,529) |
|
Taxation |
|
|
|
|
200 |
|
Loss for the financial period |
|
|
|
|
(2,329) |
|
|
|
|
|
|
|
|
|
|
|
Diagnostic Segment |
Administrative Costs |
Total |
|
Twelve months ended 30 June 2025 |
|
|
£'000 |
£'000 |
£'000 |
|
Revenue and other income |
|
|
954 |
- |
954 |
|
Costs |
|
|
(4,233) |
(2,101) |
(6,334) |
|
Operating loss |
|
|
(3,279) |
(2,101) |
(5,380) |
|
Net Finance costs |
|
|
|
|
(46) |
|
Loss on ordinary activities before taxation |
|
|
|
|
(5,426) |
|
Taxation |
|
|
|
|
195 |
|
Loss for the financial period |
|
|
|
|
(5,231) |
5. Finance income and costs
|
|
31 December |
31 December |
30 June |
|
|
2025 |
2024 |
2025 |
|
|
£000 |
£000 |
£000 |
|
Interest income on bank deposits |
3 |
41 |
43 |
|
|
31 December |
31 December |
30 June |
|
|
2025 |
2024 |
2025 |
|
|
£000 |
£000 |
£000 |
|
|
|
|
|
|
Transaction costs relating to share issue |
- |
- |
(89) |
|
Finance costs |
- |
- |
(89) |
6. Current tax asset
The current tax asset relates to the estimate of the refund under the R&D tax credit scheme of £0.6m (H1 2024/5: £0.9m). This includes £0.2m for the interim period to December 2025 that would be received following submission of the tax returns for the 12 months to June 2026, with receipt expected to be in the first quarter of 2027.
7. Earnings per share
The basic earnings per share is calculated by dividing the earnings attributable to ordinary shareholders for the year by the weighted average number of ordinary shares in issue during the period. The weighted average number of shares in issue during the period was 836,326,732 (H1 2024/5: 543,141,481). As the Company is loss-making, no potentially dilutive options have been added into the EPS calculation. (H1 2024/5: no shares).
8. Share capital
|
Allotted, issued and fully paid: |
|
No |
£000 |
|
Balance at 30 June 2024 and 31 December 2024 |
|
543,141,481 |
8,147 |
|
Share issue: April 2025 |
|
81,753,927 |
1,226 |
|
Balance at 30 June 2025 |
|
624,895,408 |
9,373 |
|
Share issue: September 2025 |
|
400,000,000 |
60 |
|
Share issue: October 2025 |
|
4,708,584 |
1 |
|
Balance at 31 December 2025 |
|
1,029,603,992 |
9,434 |
9. Other Reserves
|
|
Share Premium Account £000 |
Shares to be issued £000 |
Employee Share Incentive Plan Reserve £000 |
Share Options Reserve £000 |
Reverse Acquisitions Reserve £000 |
Total £000 |
||||
|
|
|
|
|
|
|
|
|
|||
|
At 30 June 2024 |
54,930 |
720 |
(196) |
1,698 |
(2,496) |
54,656 |
||||
|
Equity settled share-based payments |
- |
- |
- |
40 |
- |
40 |
||||
|
At 31 December 2024 |
54,930 |
720 |
(196) |
1,738 |
(2,496) |
54,696 |
||||
|
Equity settled share-based payments |
- |
- |
- |
44 |
- |
44 |
||||
|
At 30 June 2025 |
54,930 |
720 |
(196) |
1,782 |
(2,496) |
54,740 |
||||
|
Share issue: September 2025 |
480 |
- |
- |
- |
- |
480 |
||||
|
Share issue: October 2025 |
9 |
- |
- |
- |
- |
9 |
||||
|
Equity settled share-based payments |
- |
- |
- |
38 |
- |
38 |
||||
|
At 31 December 2025 |
55,419 |
720 |
(196) |
1,820 |
(2,496) |
55,267 |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE